Stocks of Gilead Sciences Inc. (NASDAQ:GILD) traded higher last session on Wall Street, up 3.05% to $78.40.
According to the data, Gilead Sciences Inc. (NASDAQ:GILD) has 30 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $115.00 and a low of $77.00, we find $90.00. Given the previous closing price of $76.08, this indicates a potential upside of 18.3 percent. GILD stock price is now -2.73% away from the 50-day moving average and -0.03% away from the 200-day moving average. The market capitalization of the company currently stands at $95.68B.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
A total of 17 analysts have issued a hold rating and 12 have given it a buy rating. Brokers who have rated the stock have averaged $92.16 as their price target over the next twelve months.
With the price target enhanced from $90 to $100, BMO Capital Markets Upgraded its rating from Market Perform to Outperform for Gilead Sciences Inc. (NASDAQ: GILD).
In other news, Parsey Merdad, Chief Medical Officer sold 6,126 shares of the company’s stock on Mar 13. The stock was sold for $483,893 at an average price of $78.99. Upon completion of the transaction, the Chief Medical Officer now directly owns 70,130 shares in the company, valued at $5.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, Chief Medical Officer Parsey Merdad sold 12,984 shares of the business’s stock. A total of $1,038,225 was realized by selling the stock at an average price of $79.96. This leaves the insider owning 70,130 shares of the company worth $5.5 million. Insiders disposed of 218,827 shares of company stock worth roughly $17.16 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by FARMER STEVEN PATRICK during the first quarter worth $102,681,000. JUPITER ASSET MANAGEMENT LTD invested $28,142,000 in shares of GILD during the first quarter. In the first quarter, OFI INVEST ASSET MANAGEMENT acquired a new stake in Gilead Sciences Inc. valued at approximately $18,285,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in GILD for approximately $16,977,000. INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC purchased a new stake in GILD valued at around $13,028,000 in the second quarter. In total, there are 2,365 active investors with 83.00% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $75.76 for Gilead Sciences Inc. (NASDAQ: GILD). During the past 12 months, Gilead Sciences Inc. has had a low of $57.17 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.20, a current ratio of 1.30, and a quick ratio of 1.10. According to the stock market information, the enterprise value for the company is $117.16B, which is based on a 17.72 price-to-earnings ratio, a 7.71 price-to-earnings-growth ratio, and a beta of 0.41. The fifty day moving average price for GILD is $80.55 and a two-hundred day moving average price translates $78.49 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.37, missing analysts’ expectations of $1.54 by -0.17. This compares to $0.01 EPS in the same period last year. The net profit margin was 20.60% and return on equity was 26.70% for GILD. The company reported revenue of $6.35 billion for the quarter, compared to $6.59 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.61 percent. For the current quarter, analysts expect GILD to generate $6.48B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/29/2023. Investors who held shares on 06/15/2023 were paid a $0.75 dividend. On an annualized basis, this represents a $3.00 dividend and a 3.83% percent yield. There was an ex-dividend date of 06/14/2023 for this dividend. In terms of dividend payout ratio, GILD is presently at 66.00%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
